The biotech industry has acquired a notable level of relevance in recent years. The arrival of the pandemic and the need to combat an unknown disease put science in the spotlight.
Argentina has great potential in this field, with a level of highly qualified professionals, a strong pharmaceutical industry, a committed health authority and the necessary infrastructure to position itself in the international market.
At mAbxience we manufacture biosimilar monoclonal antibodies, which are targeted therapies against certain types of cancer and autoimmune diseases. Our products supply throughout the country, and are already exported to the entire region, Africa and the Middle East.
During the pandemic Covid-19, mAbxience also helped develop a hyperimmune equine serum to treat moderate to severe cases of the disease, and manufactured more than two hundred million doses of the Oxford-AstraZeneca SARS-CoV2 vaccine.
On the other hand, our plant located in Garín recently obtained the European certification of Good Manufacturing Practices, which will allow us to expand our business on the other side of the Atlantic. Also in 2021, together with Sinergium Biotech, we were selected by the WHO and PAHO to develop and manufacture a vaccine with mRNA technology for Latin America. This project will allow us to have a modern and flexible platform for the generation of vaccines and targeted treatments in Argentina.
*Lucas Filgueira Risso, COO of mAbxience.
by Lucas Filgueira Risso*
